ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
PCYC-1146-IM: Phase 1/2 Dose Finding and Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
Protocol ID
PCYC-1146-IM
Condition/s
Chronic Graft Versus Host Disease
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Sponsor
Pharmacyclics LLC.
Collaborators
Janssen Research & Development, LLC
Links
External Registry ≫
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
Part A – 1 to 12 years Part B – 1 to 22 years
International registry ID's
NCT03790332
Back to Registry
Study Title PCYC-1146-IM: Phase 1/2 Dose Finding and Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
Protocol ID PCYC-1146-IM
Disease (Sub Disease) Chronic Graft Versus Host Disease
Diagnosis Stage New Diagnosis
Relapse/Refractory
Sponsor Pharmacyclics LLC.
Collaborators Janssen Research & Development, LLC
Links https://clinicaltrials.gov/ct2/show/NCT03790332
Trial Status Closed to Recruitment
Trial Open Date 22/01/2019
Study Type Treatment
Phase Phase 1/2
Age Eligibility Part A – 1 to 12 years Part B – 1 to 22 years
International registry ID's NCT03790332

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.